Cost-effectiveness of dapagliflozin versus DPP-4 inhibitors as an add-on to Metformin in the Treatment of Type 2 Diabetes Mellitus from ... View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2015-06

AUTHORS

M. Charokopou, P. McEwan, S. Lister, L. Callan, K. Bergenheim, K. Tolley, R. Postema, R. Townsend, M. Roudaut

ABSTRACT

BACKGROUND: Type 2 diabetes mellitus (T2DM) is a chronic, progressive condition where the primary treatment goal is to maintain control of glycated haemoglobin (HbA1c). In order for healthcare decision makers to ensure patients receive the highest standard of care within the available budget, the clinical benefits of each treatment option must be balanced against the economic consequences. The aim of this study was to assess the cost-effectiveness of dapagliflozin, the first-in-class sodium-glucose co-transporter 2 (SGLT2) inhibitor, compared with a dipeptidyl peptidase-4 inhibitor (DPP-4i), when added to metformin for the treatment of patients with T2DM inadequately controlled on metformin alone. METHODS: The previously published and validated Cardiff diabetes model was used as the basis for this economic evaluation, with treatment effect parameters sourced from a systematic review and network meta-analysis. Costs, derived from a UK healthcare system perspective, and quality-adjusted life years (QALYs), were used to present the final outcome as an incremental cost-effectiveness ratio (ICER) over a lifetime horizon. Univariate and probabilistic sensitivity analyses (PSA) were carried out to assess uncertainty in the model results. RESULTS: Compared with DPP-4i, dapagliflozin was associated with a mean incremental benefit of 0.032 QALYs (95% confidence interval [CI]: -0.022, 0.140) and with an incremental cost of £216 (95% CI: £-258, £795). This resulted in an ICER point estimate of £6,761 per QALY gained. Sensitivity analysis determined incremental costs to be insensitive to variation in most parameters, with only the treatment effect on weight having a notable impact on the incremental QALYs; however, there were no scenarios which raised the ICER above £15,000 per QALY. The PSA estimated that dapagliflozin had an 85% probability of being cost-effective at a willingness-to-pay threshold of £20,000 per QALY gained. CONCLUSIONS: Dapagliflozin in combination with metformin was shown to be a cost-effective treatment option from a UK healthcare system perspective for patients with T2DM who are inadequately controlled on metformin alone. More... »

PAGES

496

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/s12913-015-1139-y

DOI

http://dx.doi.org/10.1186/s12913-015-1139-y

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1010765474

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/26541516


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/08", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Information and Computing Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/0807", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Library and Information Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1110", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Nursing", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1117", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Public Health and Health Services", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Benzhydryl Compounds", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cost-Benefit Analysis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Diabetes Mellitus, Type 2", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Dipeptidyl-Peptidase IV Inhibitors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Therapy, Combination", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Glucosides", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Hypoglycemic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Metformin", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Models, Economic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Quality of Life", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Quality-Adjusted Life Years", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Sodium-Glucose Transport Proteins", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "State Medicine", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "United Kingdom", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Pharmerit International, Rotterdam, Netherlands", 
          "id": "http://www.grid.ac/institutes/grid.482836.3", 
          "name": [
            "Pharmerit International, Rotterdam, Netherlands"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Charokopou", 
        "givenName": "M.", 
        "id": "sg:person.0655577401.10", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0655577401.10"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "HEOR, Monmouth, UK", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Centre for Health Economics, Swansea University, Swansea, UK", 
            "HEOR, Monmouth, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "McEwan", 
        "givenName": "P.", 
        "id": "sg:person.01346767345.38", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01346767345.38"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Bristol-Myers Squibb Pharmaceuticals Ltd, Uxbridge, UK", 
          "id": "http://www.grid.ac/institutes/grid.432583.b", 
          "name": [
            "Bristol-Myers Squibb Pharmaceuticals Ltd, Uxbridge, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lister", 
        "givenName": "S.", 
        "id": "sg:person.0676512523.46", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0676512523.46"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "AstraZeneca UK Ltd, Luton, UK", 
          "id": "http://www.grid.ac/institutes/grid.417815.e", 
          "name": [
            "AstraZeneca UK Ltd, Luton, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Callan", 
        "givenName": "L.", 
        "id": "sg:person.010077463552.18", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010077463552.18"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "AstraZeneca, Molndal, 431 83 Sweden", 
          "id": "http://www.grid.ac/institutes/grid.418151.8", 
          "name": [
            "AstraZeneca, Molndal, 431 83 Sweden"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Bergenheim", 
        "givenName": "K.", 
        "id": "sg:person.0700022153.26", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0700022153.26"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Tolley Health Economics Ltd., Buxton, UK", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Tolley Health Economics Ltd., Buxton, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Tolley", 
        "givenName": "K.", 
        "id": "sg:person.01132355051.83", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01132355051.83"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Bristol-Myers Squibb, Rueil-Malmaison, France", 
          "id": "http://www.grid.ac/institutes/grid.481843.2", 
          "name": [
            "Bristol-Myers Squibb, Rueil-Malmaison, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Postema", 
        "givenName": "R.", 
        "id": "sg:person.01100372171.43", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01100372171.43"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "AstraZeneca, Brussels, Belgium", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "AstraZeneca, Brussels, Belgium"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Townsend", 
        "givenName": "R.", 
        "id": "sg:person.01270616201.88", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01270616201.88"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Bristol-Myers Squibb, Rueil-Malmaison, France", 
          "id": "http://www.grid.ac/institutes/grid.481843.2", 
          "name": [
            "Bristol-Myers Squibb, Rueil-Malmaison, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Roudaut", 
        "givenName": "M.", 
        "id": "sg:person.01365107104.86", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01365107104.86"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s40261-013-0155-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1051450610", 
          "https://doi.org/10.1007/s40261-013-0155-0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00125-004-1527-z", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1036304902", 
          "https://doi.org/10.1007/s00125-004-1527-z"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00125-013-2940-y", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010988781", 
          "https://doi.org/10.1007/s00125-013-2940-y"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2015-06", 
    "datePublishedReg": "2015-06-01", 
    "description": "BACKGROUND: Type 2 diabetes mellitus (T2DM) is a chronic, progressive condition where the primary treatment goal is to maintain control of glycated haemoglobin (HbA1c). In order for healthcare decision makers to ensure patients receive the highest standard of care within the available budget, the clinical benefits of each treatment option must be balanced against the economic consequences. The aim of this study was to assess the cost-effectiveness of dapagliflozin, the first-in-class sodium-glucose co-transporter 2 (SGLT2) inhibitor, compared with a dipeptidyl peptidase-4 inhibitor (DPP-4i), when added to metformin for the treatment of patients with T2DM inadequately controlled on metformin alone.\nMETHODS: The previously published and validated Cardiff diabetes model was used as the basis for this economic evaluation, with treatment effect parameters sourced from a systematic review and network meta-analysis. Costs, derived from a UK healthcare system perspective, and quality-adjusted life years (QALYs), were used to present the final outcome as an incremental cost-effectiveness ratio (ICER) over a lifetime horizon. Univariate and probabilistic sensitivity analyses (PSA) were carried out to assess uncertainty in the model results.\nRESULTS: Compared with DPP-4i, dapagliflozin was associated with a mean incremental benefit of 0.032 QALYs (95% confidence interval [CI]: -0.022, 0.140) and with an incremental cost of \u00a3216 (95% CI: \u00a3-258, \u00a3795). This resulted in an ICER point estimate of \u00a36,761 per QALY gained. Sensitivity analysis determined incremental costs to be insensitive to variation in most parameters, with only the treatment effect on weight having a notable impact on the incremental QALYs; however, there were no scenarios which raised the ICER above \u00a315,000 per QALY. The PSA estimated that dapagliflozin had an 85% probability of being cost-effective at a willingness-to-pay threshold of \u00a320,000 per QALY gained.\nCONCLUSIONS: Dapagliflozin in combination with metformin was shown to be a cost-effective treatment option from a UK healthcare system perspective for patients with T2DM who are inadequately controlled on metformin alone.", 
    "genre": "article", 
    "id": "sg:pub.10.1186/s12913-015-1139-y", 
    "inLanguage": "en", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1327417", 
        "issn": [
          "1472-6963"
        ], 
        "name": "BMC Health Services Research", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "15"
      }
    ], 
    "keywords": [
      "quality-adjusted life years", 
      "incremental cost-effectiveness ratio", 
      "probabilistic sensitivity analyses", 
      "healthcare system perspective", 
      "incremental cost", 
      "incremental quality-adjusted life years", 
      "dipeptidyl peptidase-4 inhibitors", 
      "cost-effectiveness ratio", 
      "Cardiff Diabetes Model", 
      "healthcare decision makers", 
      "cost-effective treatment option", 
      "economic evaluation", 
      "sensitivity analysis", 
      "economic consequences", 
      "life years", 
      "treatment effect parameters", 
      "lifetime horizon", 
      "systems perspective", 
      "decision makers", 
      "treatment options", 
      "available budget", 
      "type 2 diabetes mellitus", 
      "point estimates", 
      "incremental benefit", 
      "peptidase-4 inhibitors", 
      "treatment of patients", 
      "DPP-4 inhibitors", 
      "primary treatment goal", 
      "cost", 
      "diabetes mellitus", 
      "clinical benefit", 
      "glycated hemoglobin", 
      "progressive condition", 
      "diabetes model", 
      "treatment goals", 
      "dapagliflozin", 
      "metformin", 
      "systematic review", 
      "type 2", 
      "notable impact", 
      "willingness", 
      "patients", 
      "makers", 
      "mellitus", 
      "high standards", 
      "T2DM", 
      "model results", 
      "treatment effects", 
      "benefits", 
      "perspective", 
      "final outcome", 
      "inhibitors", 
      "options", 
      "budget", 
      "effect parameters", 
      "horizon", 
      "treatment", 
      "uncertainty", 
      "impact", 
      "estimates", 
      "most parameters", 
      "care", 
      "hemoglobin", 
      "probability", 
      "outcomes", 
      "model", 
      "analysis", 
      "consequences", 
      "scenarios", 
      "review", 
      "aim", 
      "years", 
      "standards", 
      "goal", 
      "control", 
      "weight", 
      "evaluation", 
      "study", 
      "effect", 
      "threshold", 
      "combination", 
      "results", 
      "basis", 
      "ratio", 
      "order", 
      "variation", 
      "class", 
      "parameters", 
      "conditions", 
      "network", 
      "UK healthcare system perspective", 
      "mean incremental benefit", 
      "ICER point estimate"
    ], 
    "name": "Cost-effectiveness of dapagliflozin versus DPP-4 inhibitors as an add-on to Metformin in the Treatment of Type 2 Diabetes Mellitus from a UK Healthcare System Perspective", 
    "pagination": "496", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1010765474"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/s12913-015-1139-y"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "26541516"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/s12913-015-1139-y", 
      "https://app.dimensions.ai/details/publication/pub.1010765474"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2021-11-01T18:23", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20211101/entities/gbq_results/article/article_650.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1186/s12913-015-1139-y"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/s12913-015-1139-y'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/s12913-015-1139-y'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/s12913-015-1139-y'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/s12913-015-1139-y'


 

This table displays all metadata directly associated to this object as RDF triples.

314 TRIPLES      22 PREDICATES      141 URIs      127 LITERALS      22 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/s12913-015-1139-y schema:about N0dc17396e4404aebaad097b7ab3f54fa
2 N1145e15a04c744efaddd27cc1f30dbff
3 N128e172485cb40b19144f7df6ea6835c
4 N154df1f599f24f4f8bc54fdc358ca83a
5 N3124db40ea0649d6815222997802f3c3
6 N5ec8828ad3f24d2f97f8bac8c4cdb8ae
7 N9d02a935bada48088ef5e6fb0abbde02
8 Nbe136c76bbc142a79ea5ff43bdf7e591
9 Nce1fc8492b2a4593a3646aaf4dbc7f9f
10 Ncec94b89c15f4df4a8edf746bb8c6ebc
11 Nd7acb7fec953436d9ce99050be2c4cbf
12 Nd90c58254d1845ac8824377534d93cc4
13 Ne71b5d196e614b8289f741ac77faa65d
14 Nf3a11ba509a44e809d3d0f278d91fcb7
15 Nfb29c5e7f5e443db99d1101ac43b7077
16 anzsrc-for:08
17 anzsrc-for:0807
18 anzsrc-for:11
19 anzsrc-for:1110
20 anzsrc-for:1117
21 schema:author N6e1f8ea6ab694555b003f407190f7be7
22 schema:citation sg:pub.10.1007/s00125-004-1527-z
23 sg:pub.10.1007/s00125-013-2940-y
24 sg:pub.10.1007/s40261-013-0155-0
25 schema:datePublished 2015-06
26 schema:datePublishedReg 2015-06-01
27 schema:description BACKGROUND: Type 2 diabetes mellitus (T2DM) is a chronic, progressive condition where the primary treatment goal is to maintain control of glycated haemoglobin (HbA1c). In order for healthcare decision makers to ensure patients receive the highest standard of care within the available budget, the clinical benefits of each treatment option must be balanced against the economic consequences. The aim of this study was to assess the cost-effectiveness of dapagliflozin, the first-in-class sodium-glucose co-transporter 2 (SGLT2) inhibitor, compared with a dipeptidyl peptidase-4 inhibitor (DPP-4i), when added to metformin for the treatment of patients with T2DM inadequately controlled on metformin alone. METHODS: The previously published and validated Cardiff diabetes model was used as the basis for this economic evaluation, with treatment effect parameters sourced from a systematic review and network meta-analysis. Costs, derived from a UK healthcare system perspective, and quality-adjusted life years (QALYs), were used to present the final outcome as an incremental cost-effectiveness ratio (ICER) over a lifetime horizon. Univariate and probabilistic sensitivity analyses (PSA) were carried out to assess uncertainty in the model results. RESULTS: Compared with DPP-4i, dapagliflozin was associated with a mean incremental benefit of 0.032 QALYs (95% confidence interval [CI]: -0.022, 0.140) and with an incremental cost of £216 (95% CI: £-258, £795). This resulted in an ICER point estimate of £6,761 per QALY gained. Sensitivity analysis determined incremental costs to be insensitive to variation in most parameters, with only the treatment effect on weight having a notable impact on the incremental QALYs; however, there were no scenarios which raised the ICER above £15,000 per QALY. The PSA estimated that dapagliflozin had an 85% probability of being cost-effective at a willingness-to-pay threshold of £20,000 per QALY gained. CONCLUSIONS: Dapagliflozin in combination with metformin was shown to be a cost-effective treatment option from a UK healthcare system perspective for patients with T2DM who are inadequately controlled on metformin alone.
28 schema:genre article
29 schema:inLanguage en
30 schema:isAccessibleForFree true
31 schema:isPartOf N018247676c2a4d9e941a130acbb73f79
32 Nc713479b24844232b3399fd3d03ee737
33 sg:journal.1327417
34 schema:keywords Cardiff Diabetes Model
35 DPP-4 inhibitors
36 ICER point estimate
37 T2DM
38 UK healthcare system perspective
39 aim
40 analysis
41 available budget
42 basis
43 benefits
44 budget
45 care
46 class
47 clinical benefit
48 combination
49 conditions
50 consequences
51 control
52 cost
53 cost-effective treatment option
54 cost-effectiveness ratio
55 dapagliflozin
56 decision makers
57 diabetes mellitus
58 diabetes model
59 dipeptidyl peptidase-4 inhibitors
60 economic consequences
61 economic evaluation
62 effect
63 effect parameters
64 estimates
65 evaluation
66 final outcome
67 glycated hemoglobin
68 goal
69 healthcare decision makers
70 healthcare system perspective
71 hemoglobin
72 high standards
73 horizon
74 impact
75 incremental benefit
76 incremental cost
77 incremental cost-effectiveness ratio
78 incremental quality-adjusted life years
79 inhibitors
80 life years
81 lifetime horizon
82 makers
83 mean incremental benefit
84 mellitus
85 metformin
86 model
87 model results
88 most parameters
89 network
90 notable impact
91 options
92 order
93 outcomes
94 parameters
95 patients
96 peptidase-4 inhibitors
97 perspective
98 point estimates
99 primary treatment goal
100 probabilistic sensitivity analyses
101 probability
102 progressive condition
103 quality-adjusted life years
104 ratio
105 results
106 review
107 scenarios
108 sensitivity analysis
109 standards
110 study
111 systematic review
112 systems perspective
113 threshold
114 treatment
115 treatment effect parameters
116 treatment effects
117 treatment goals
118 treatment of patients
119 treatment options
120 type 2
121 type 2 diabetes mellitus
122 uncertainty
123 variation
124 weight
125 willingness
126 years
127 schema:name Cost-effectiveness of dapagliflozin versus DPP-4 inhibitors as an add-on to Metformin in the Treatment of Type 2 Diabetes Mellitus from a UK Healthcare System Perspective
128 schema:pagination 496
129 schema:productId N738b8b6a5a784578b953e2e90256a6b7
130 N9253f4e9a9e34e42ad1bd32d6c72a156
131 Nf8473cb958a648bd9d7949faebe4cb44
132 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010765474
133 https://doi.org/10.1186/s12913-015-1139-y
134 schema:sdDatePublished 2021-11-01T18:23
135 schema:sdLicense https://scigraph.springernature.com/explorer/license/
136 schema:sdPublisher Nb62ab71b6c004b889d485d1654f04b5b
137 schema:url https://doi.org/10.1186/s12913-015-1139-y
138 sgo:license sg:explorer/license/
139 sgo:sdDataset articles
140 rdf:type schema:ScholarlyArticle
141 N018247676c2a4d9e941a130acbb73f79 schema:volumeNumber 15
142 rdf:type schema:PublicationVolume
143 N0804555a22014c9788f4a59d27119868 rdf:first sg:person.01270616201.88
144 rdf:rest Ncf4befa3bde54ea5abeedc272a51acb1
145 N0dc17396e4404aebaad097b7ab3f54fa schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
146 schema:name State Medicine
147 rdf:type schema:DefinedTerm
148 N1145e15a04c744efaddd27cc1f30dbff schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
149 schema:name Metformin
150 rdf:type schema:DefinedTerm
151 N128e172485cb40b19144f7df6ea6835c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
152 schema:name Dipeptidyl-Peptidase IV Inhibitors
153 rdf:type schema:DefinedTerm
154 N154df1f599f24f4f8bc54fdc358ca83a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
155 schema:name Diabetes Mellitus, Type 2
156 rdf:type schema:DefinedTerm
157 N172eff8ebcf541bd842361ae29e8e15e rdf:first sg:person.01346767345.38
158 rdf:rest Nee4bcd44348e41d8896e1112575f4bd3
159 N3124db40ea0649d6815222997802f3c3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
160 schema:name Models, Economic
161 rdf:type schema:DefinedTerm
162 N3a211fb502824baaa6eb2fae60b59fa6 rdf:first sg:person.0700022153.26
163 rdf:rest Nb74948af10fc45de8749b76f1197c24e
164 N5ec8828ad3f24d2f97f8bac8c4cdb8ae schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
165 schema:name Hypoglycemic Agents
166 rdf:type schema:DefinedTerm
167 N6e1f8ea6ab694555b003f407190f7be7 rdf:first sg:person.0655577401.10
168 rdf:rest N172eff8ebcf541bd842361ae29e8e15e
169 N738b8b6a5a784578b953e2e90256a6b7 schema:name dimensions_id
170 schema:value pub.1010765474
171 rdf:type schema:PropertyValue
172 N8cedd4269c054b07a8aa5c7a08ca8ab4 rdf:first sg:person.01100372171.43
173 rdf:rest N0804555a22014c9788f4a59d27119868
174 N9253f4e9a9e34e42ad1bd32d6c72a156 schema:name doi
175 schema:value 10.1186/s12913-015-1139-y
176 rdf:type schema:PropertyValue
177 N9d02a935bada48088ef5e6fb0abbde02 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
178 schema:name United Kingdom
179 rdf:type schema:DefinedTerm
180 Nb62ab71b6c004b889d485d1654f04b5b schema:name Springer Nature - SN SciGraph project
181 rdf:type schema:Organization
182 Nb74948af10fc45de8749b76f1197c24e rdf:first sg:person.01132355051.83
183 rdf:rest N8cedd4269c054b07a8aa5c7a08ca8ab4
184 Nbe136c76bbc142a79ea5ff43bdf7e591 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
185 schema:name Drug Therapy, Combination
186 rdf:type schema:DefinedTerm
187 Nc713479b24844232b3399fd3d03ee737 schema:issueNumber 1
188 rdf:type schema:PublicationIssue
189 Nce1fc8492b2a4593a3646aaf4dbc7f9f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
190 schema:name Sodium-Glucose Transport Proteins
191 rdf:type schema:DefinedTerm
192 Ncec94b89c15f4df4a8edf746bb8c6ebc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
193 schema:name Quality of Life
194 rdf:type schema:DefinedTerm
195 Ncf4befa3bde54ea5abeedc272a51acb1 rdf:first sg:person.01365107104.86
196 rdf:rest rdf:nil
197 Nd7acb7fec953436d9ce99050be2c4cbf schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
198 schema:name Cost-Benefit Analysis
199 rdf:type schema:DefinedTerm
200 Nd90c58254d1845ac8824377534d93cc4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
201 schema:name Quality-Adjusted Life Years
202 rdf:type schema:DefinedTerm
203 Ne71b5d196e614b8289f741ac77faa65d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
204 schema:name Glucosides
205 rdf:type schema:DefinedTerm
206 Nee4bcd44348e41d8896e1112575f4bd3 rdf:first sg:person.0676512523.46
207 rdf:rest Nf43585af173a474eba3fcf8048e170a2
208 Nf3a11ba509a44e809d3d0f278d91fcb7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
209 schema:name Humans
210 rdf:type schema:DefinedTerm
211 Nf43585af173a474eba3fcf8048e170a2 rdf:first sg:person.010077463552.18
212 rdf:rest N3a211fb502824baaa6eb2fae60b59fa6
213 Nf8473cb958a648bd9d7949faebe4cb44 schema:name pubmed_id
214 schema:value 26541516
215 rdf:type schema:PropertyValue
216 Nfb29c5e7f5e443db99d1101ac43b7077 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
217 schema:name Benzhydryl Compounds
218 rdf:type schema:DefinedTerm
219 anzsrc-for:08 schema:inDefinedTermSet anzsrc-for:
220 schema:name Information and Computing Sciences
221 rdf:type schema:DefinedTerm
222 anzsrc-for:0807 schema:inDefinedTermSet anzsrc-for:
223 schema:name Library and Information Studies
224 rdf:type schema:DefinedTerm
225 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
226 schema:name Medical and Health Sciences
227 rdf:type schema:DefinedTerm
228 anzsrc-for:1110 schema:inDefinedTermSet anzsrc-for:
229 schema:name Nursing
230 rdf:type schema:DefinedTerm
231 anzsrc-for:1117 schema:inDefinedTermSet anzsrc-for:
232 schema:name Public Health and Health Services
233 rdf:type schema:DefinedTerm
234 sg:journal.1327417 schema:issn 1472-6963
235 schema:name BMC Health Services Research
236 schema:publisher Springer Nature
237 rdf:type schema:Periodical
238 sg:person.010077463552.18 schema:affiliation grid-institutes:grid.417815.e
239 schema:familyName Callan
240 schema:givenName L.
241 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010077463552.18
242 rdf:type schema:Person
243 sg:person.01100372171.43 schema:affiliation grid-institutes:grid.481843.2
244 schema:familyName Postema
245 schema:givenName R.
246 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01100372171.43
247 rdf:type schema:Person
248 sg:person.01132355051.83 schema:affiliation grid-institutes:None
249 schema:familyName Tolley
250 schema:givenName K.
251 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01132355051.83
252 rdf:type schema:Person
253 sg:person.01270616201.88 schema:affiliation grid-institutes:None
254 schema:familyName Townsend
255 schema:givenName R.
256 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01270616201.88
257 rdf:type schema:Person
258 sg:person.01346767345.38 schema:affiliation grid-institutes:None
259 schema:familyName McEwan
260 schema:givenName P.
261 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01346767345.38
262 rdf:type schema:Person
263 sg:person.01365107104.86 schema:affiliation grid-institutes:grid.481843.2
264 schema:familyName Roudaut
265 schema:givenName M.
266 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01365107104.86
267 rdf:type schema:Person
268 sg:person.0655577401.10 schema:affiliation grid-institutes:grid.482836.3
269 schema:familyName Charokopou
270 schema:givenName M.
271 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0655577401.10
272 rdf:type schema:Person
273 sg:person.0676512523.46 schema:affiliation grid-institutes:grid.432583.b
274 schema:familyName Lister
275 schema:givenName S.
276 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0676512523.46
277 rdf:type schema:Person
278 sg:person.0700022153.26 schema:affiliation grid-institutes:grid.418151.8
279 schema:familyName Bergenheim
280 schema:givenName K.
281 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0700022153.26
282 rdf:type schema:Person
283 sg:pub.10.1007/s00125-004-1527-z schema:sameAs https://app.dimensions.ai/details/publication/pub.1036304902
284 https://doi.org/10.1007/s00125-004-1527-z
285 rdf:type schema:CreativeWork
286 sg:pub.10.1007/s00125-013-2940-y schema:sameAs https://app.dimensions.ai/details/publication/pub.1010988781
287 https://doi.org/10.1007/s00125-013-2940-y
288 rdf:type schema:CreativeWork
289 sg:pub.10.1007/s40261-013-0155-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1051450610
290 https://doi.org/10.1007/s40261-013-0155-0
291 rdf:type schema:CreativeWork
292 grid-institutes:None schema:alternateName AstraZeneca, Brussels, Belgium
293 HEOR, Monmouth, UK
294 Tolley Health Economics Ltd., Buxton, UK
295 schema:name AstraZeneca, Brussels, Belgium
296 Centre for Health Economics, Swansea University, Swansea, UK
297 HEOR, Monmouth, UK
298 Tolley Health Economics Ltd., Buxton, UK
299 rdf:type schema:Organization
300 grid-institutes:grid.417815.e schema:alternateName AstraZeneca UK Ltd, Luton, UK
301 schema:name AstraZeneca UK Ltd, Luton, UK
302 rdf:type schema:Organization
303 grid-institutes:grid.418151.8 schema:alternateName AstraZeneca, Molndal, 431 83 Sweden
304 schema:name AstraZeneca, Molndal, 431 83 Sweden
305 rdf:type schema:Organization
306 grid-institutes:grid.432583.b schema:alternateName Bristol-Myers Squibb Pharmaceuticals Ltd, Uxbridge, UK
307 schema:name Bristol-Myers Squibb Pharmaceuticals Ltd, Uxbridge, UK
308 rdf:type schema:Organization
309 grid-institutes:grid.481843.2 schema:alternateName Bristol-Myers Squibb, Rueil-Malmaison, France
310 schema:name Bristol-Myers Squibb, Rueil-Malmaison, France
311 rdf:type schema:Organization
312 grid-institutes:grid.482836.3 schema:alternateName Pharmerit International, Rotterdam, Netherlands
313 schema:name Pharmerit International, Rotterdam, Netherlands
314 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...